← Back to Home

An Alternative Immune Target in Multiple Myeloma: Early Cevostamab Trial Shows Durable Remissions in Some Patients

This bispecific antibody bypasses the commonly targeted BCMA and produced responses in about four in ten patients who had undergone multiple lines of therapy. Efficacy could be maintained after a limited treatment course, but infections, serious adverse events, and the early-stage trial design also set clear boundaries on the findings.

By SURL BioNews

Treatment options for multiple myeloma are increasing, yet the path forward often narrows as the disease relapses. When patients have stopped responding to several classes of drugs and have even received cell therapy or other bispecific antibodies, targeting a different tumor antigen may offer another way forward. A phase 1 trial published in *Nature Medicine* showed that FcRH5-targeting cevostamab could produce remissions lasting for months in some heavily pretreated patients, with some continuing even after treatment ended.

This multicenter, open-label study, registered as NCT03275103 and also known as GO39775, enrolled 324 patients with relapsed or refractory multiple myeloma. Participants had received a median of six prior lines of therapy, and 89.5% had disease refractory to all three major treatment classes: proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. A total of 47.5% had previously received BCMA-targeted therapy. The trial allowed enrollment of patients previously treated with CAR-T, antibody-drug conjugates, and bispecific antibodies, reflecting a population with very limited clinical options.

One end of cevostamab recognizes FcRH5 on myeloma cells, while the other binds CD3 on the surface of T cells, bringing immune cells closer to the tumor. FcRH5 differs from the commonly targeted BCMA and could theoretically provide another point of attack after prior BCMA therapy has failed. Treatment was administered by intravenous infusion, with step-up dosing during the first week followed by dosing once every three weeks for up to 17 cycles, or about 12 months, rather than continuing indefinitely.

Among 323 patients evaluable for efficacy, the objective response rate was 42.1%, and 25.1% achieved a very good partial response or better. Among responding patients, the median duration of response was 11.2 months. The recommended phase 2 target dose selected by the study was 160 mg, and the response rate among the 167 patients who received this dose was 44.3%. Among those who had not previously received BCMA-targeted therapy, the response rate reached 60.6%, with a median duration of response of 19.7 months. Results were weaker among those who had received such therapy, suggesting that prior treatment history may affect subsequent benefit. However, these were not randomized comparison groups, so no conclusions about treatment sequencing can be drawn from them.

The fixed treatment course is one of the study’s more practically significant features. In the 160 mg group, 26 responding patients completed all 17 cycles. At the data cutoff, responses were still ongoing after treatment discontinuation in 17 patients, including five whose responses had lasted at least 30 months from the start of treatment. However, a post hoc analysis of the overall population showed a median progression-free survival of only 2.8 months, underscoring that the longer duration of response describes the minority of patients who successfully achieved a response and does not represent everyone who received treatment.

Safety must also be considered. Across all participants, 59.6% experienced grade 3 or 4 adverse events, and 60.2% experienced serious adverse events. Excluding disease progression, 15 patients experienced grade 5, or fatal, events, three of which investigators considered treatment-related. Cytokine release syndrome was the most common event, occurring in 77.8% of patients. In the subgroup receiving the ultimately selected three-step dose-escalation regimen, all cases were grade 1 or 2. In the 160 mg group, 15.6% also experienced grade 3 or 4 infections, highlighting the need to manage immune activation, low blood cell counts, and infection risk together.

This was a phase 1 study focused primarily on safety and dose finding. It had no control group, included multiple doses and step-up dosing approaches, and efficacy was assessed by investigators according to standard criteria. It is therefore not sufficient to establish that cevostamab is superior to existing therapies. Its more credible finding is that FcRH5 may indeed be a viable target beyond BCMA and that some patients can maintain remission after a limited treatment course. Further trials are still needed to determine which patients are most likely to benefit, where the treatment should be placed in the treatment sequence, and whether fatal toxicity can be controlled in larger studies.

References

  1. Nature Medicine
  2. ClinicalTrials.gov
  3. Roche Medical / ASH 2024